Concepts (211)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Squamous Cell | 10 | 2022 | 162 | 4.320 |
Why?
|
| Head and Neck Neoplasms | 13 | 2023 | 138 | 3.850 |
Why?
|
| Parotid Neoplasms | 3 | 2021 | 14 | 2.000 |
Why?
|
| Oropharyngeal Neoplasms | 4 | 2022 | 19 | 1.900 |
Why?
|
| Tongue Neoplasms | 3 | 2021 | 18 | 1.880 |
Why?
|
| Laryngeal Neoplasms | 5 | 2023 | 28 | 1.830 |
Why?
|
| Robotic Surgical Procedures | 3 | 2020 | 26 | 1.640 |
Why?
|
| Adenocarcinoma | 2 | 2021 | 135 | 1.220 |
Why?
|
| Neck Dissection | 3 | 2021 | 18 | 1.160 |
Why?
|
| Retrospective Studies | 23 | 2023 | 2993 | 1.150 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2022 | 202 | 1.040 |
Why?
|
| Facial Nerve | 3 | 2021 | 10 | 1.000 |
Why?
|
| Dissection | 3 | 2021 | 22 | 0.990 |
Why?
|
| Parotid Gland | 3 | 2021 | 17 | 0.990 |
Why?
|
| Lymphatic Metastasis | 3 | 2021 | 86 | 0.950 |
Why?
|
| Salvage Therapy | 3 | 2023 | 32 | 0.900 |
Why?
|
| Postoperative Complications | 5 | 2020 | 812 | 0.880 |
Why?
|
| Humans | 38 | 2023 | 23187 | 0.870 |
Why?
|
| Papillomavirus Infections | 2 | 2022 | 16 | 0.840 |
Why?
|
| Drug Utilization | 2 | 2020 | 20 | 0.800 |
Why?
|
| Narcotics | 2 | 2020 | 34 | 0.780 |
Why?
|
| Analgesia | 2 | 2020 | 34 | 0.770 |
Why?
|
| Male | 25 | 2023 | 12659 | 0.760 |
Why?
|
| Alphapapillomavirus | 1 | 2022 | 6 | 0.740 |
Why?
|
| Middle Aged | 20 | 2021 | 7981 | 0.720 |
Why?
|
| Survival Rate | 8 | 2021 | 320 | 0.720 |
Why?
|
| Aged | 19 | 2023 | 7660 | 0.700 |
Why?
|
| Gloves, Surgical | 1 | 2021 | 7 | 0.670 |
Why?
|
| Neoplasm Seeding | 1 | 2021 | 9 | 0.670 |
Why?
|
| Surgical Instruments | 1 | 2021 | 24 | 0.670 |
Why?
|
| Adenolymphoma | 1 | 2020 | 4 | 0.660 |
Why?
|
| Adenoma, Pleomorphic | 1 | 2020 | 6 | 0.660 |
Why?
|
| Female | 22 | 2021 | 13142 | 0.660 |
Why?
|
| Otorhinolaryngologic Surgical Procedures | 1 | 2021 | 28 | 0.660 |
Why?
|
| Glottis | 1 | 2020 | 3 | 0.660 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2020 | 23 | 0.650 |
Why?
|
| Neoplasm Grading | 2 | 2021 | 50 | 0.650 |
Why?
|
| Prescriptions | 1 | 2020 | 16 | 0.640 |
Why?
|
| Pain, Postoperative | 2 | 2020 | 272 | 0.640 |
Why?
|
| Chemoradiotherapy | 3 | 2023 | 57 | 0.620 |
Why?
|
| Recovery of Function | 1 | 2020 | 242 | 0.610 |
Why?
|
| Human papillomavirus 16 | 1 | 2019 | 6 | 0.600 |
Why?
|
| Pharyngeal Neoplasms | 1 | 2019 | 4 | 0.600 |
Why?
|
| Pharyngectomy | 1 | 2019 | 3 | 0.600 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2019 | 63 | 0.580 |
Why?
|
| Sarcoma | 1 | 2021 | 140 | 0.560 |
Why?
|
| Databases, Factual | 4 | 2021 | 310 | 0.470 |
Why?
|
| Adult | 13 | 2020 | 6959 | 0.460 |
Why?
|
| Tonsillar Neoplasms | 1 | 2014 | 3 | 0.420 |
Why?
|
| Meningeal Neoplasms | 1 | 2014 | 11 | 0.420 |
Why?
|
| Dura Mater | 1 | 2014 | 15 | 0.410 |
Why?
|
| Laryngectomy | 4 | 2023 | 16 | 0.410 |
Why?
|
| Teratoma | 1 | 2012 | 3 | 0.380 |
Why?
|
| Surgical Flaps | 1 | 2012 | 50 | 0.370 |
Why?
|
| Laryngeal Edema | 1 | 2011 | 2 | 0.360 |
Why?
|
| Angioedema | 1 | 2011 | 2 | 0.360 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2011 | 16 | 0.350 |
Why?
|
| Airway Obstruction | 1 | 2011 | 16 | 0.350 |
Why?
|
| Neoplasm Staging | 4 | 2021 | 353 | 0.350 |
Why?
|
| Laryngeal Diseases | 1 | 2011 | 3 | 0.350 |
Why?
|
| Ear Diseases | 1 | 2011 | 2 | 0.350 |
Why?
|
| Nose Diseases | 1 | 2011 | 6 | 0.350 |
Why?
|
| Nose Neoplasms | 2 | 2022 | 35 | 0.340 |
Why?
|
| Barotrauma | 1 | 2010 | 1 | 0.340 |
Why?
|
| Gravitation | 1 | 2010 | 1 | 0.340 |
Why?
|
| Ear Canal | 1 | 2010 | 2 | 0.340 |
Why?
|
| Tympanic Membrane | 1 | 2010 | 2 | 0.340 |
Why?
|
| Accidents | 1 | 2010 | 2 | 0.340 |
Why?
|
| Head Movements | 1 | 2010 | 6 | 0.340 |
Why?
|
| Leisure Activities | 1 | 2010 | 12 | 0.330 |
Why?
|
| Hypersensitivity | 1 | 2011 | 38 | 0.330 |
Why?
|
| Tongue | 2 | 2021 | 8 | 0.330 |
Why?
|
| Acceleration | 1 | 2010 | 19 | 0.330 |
Why?
|
| Edema | 1 | 2010 | 22 | 0.330 |
Why?
|
| Prognosis | 3 | 2019 | 730 | 0.330 |
Why?
|
| United States | 6 | 2021 | 1803 | 0.330 |
Why?
|
| Cohort Studies | 4 | 2020 | 1467 | 0.320 |
Why?
|
| Young Adult | 6 | 2020 | 1657 | 0.320 |
Why?
|
| Chylothorax | 1 | 2010 | 1 | 0.320 |
Why?
|
| Proportional Hazards Models | 2 | 2021 | 279 | 0.310 |
Why?
|
| Neoplasm Invasiveness | 2 | 2021 | 88 | 0.300 |
Why?
|
| Papillomaviridae | 2 | 2022 | 15 | 0.300 |
Why?
|
| Betacoronavirus | 2 | 2020 | 69 | 0.300 |
Why?
|
| Disease-Free Survival | 2 | 2019 | 171 | 0.290 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 79 | 0.290 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 82 | 0.290 |
Why?
|
| Treatment Outcome | 3 | 2020 | 2943 | 0.280 |
Why?
|
| Lens Cortex, Crystalline | 1 | 2007 | 3 | 0.270 |
Why?
|
| Lens Nucleus, Crystalline | 1 | 2007 | 6 | 0.270 |
Why?
|
| Adolescent | 4 | 2020 | 1884 | 0.270 |
Why?
|
| Lens, Crystalline | 1 | 2007 | 34 | 0.270 |
Why?
|
| Risk Assessment | 2 | 2019 | 550 | 0.260 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2018 | 29 | 0.250 |
Why?
|
| Margins of Excision | 2 | 2021 | 28 | 0.210 |
Why?
|
| Aged, 80 and over | 5 | 2020 | 3865 | 0.200 |
Why?
|
| Neck | 2 | 2023 | 23 | 0.200 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2023 | 30 | 0.200 |
Why?
|
| Otolaryngology | 2 | 2020 | 24 | 0.200 |
Why?
|
| Pilot Projects | 2 | 2022 | 369 | 0.190 |
Why?
|
| Free Tissue Flaps | 2 | 2019 | 14 | 0.190 |
Why?
|
| SEER Program | 2 | 2019 | 34 | 0.190 |
Why?
|
| Prospective Studies | 2 | 2021 | 1512 | 0.190 |
Why?
|
| Age Factors | 3 | 2019 | 651 | 0.190 |
Why?
|
| Cell-Derived Microparticles | 1 | 2022 | 5 | 0.180 |
Why?
|
| Combined Modality Therapy | 2 | 2021 | 294 | 0.180 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 2022 | 59 | 0.180 |
Why?
|
| Length of Stay | 2 | 2023 | 298 | 0.180 |
Why?
|
| Pain Measurement | 2 | 2020 | 412 | 0.170 |
Why?
|
| Chondrosarcoma | 1 | 2021 | 38 | 0.170 |
Why?
|
| Cytological Techniques | 1 | 2021 | 14 | 0.170 |
Why?
|
| Risk Factors | 3 | 2021 | 2020 | 0.170 |
Why?
|
| Otorhinolaryngologic Diseases | 1 | 2020 | 6 | 0.160 |
Why?
|
| Esthesioneuroblastoma, Olfactory | 1 | 2020 | 11 | 0.160 |
Why?
|
| Urban Health Services | 1 | 2020 | 12 | 0.160 |
Why?
|
| Aging | 1 | 2007 | 1180 | 0.160 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 26 | 0.160 |
Why?
|
| Point-of-Care Testing | 1 | 2020 | 27 | 0.160 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 1430 | 0.160 |
Why?
|
| Paraganglioma | 1 | 2019 | 3 | 0.150 |
Why?
|
| Preoperative Care | 1 | 2020 | 107 | 0.150 |
Why?
|
| Frailty | 1 | 2019 | 22 | 0.150 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2019 | 19 | 0.150 |
Why?
|
| Disease Management | 1 | 2020 | 98 | 0.150 |
Why?
|
| Genetic Heterogeneity | 1 | 2019 | 9 | 0.150 |
Why?
|
| Head | 1 | 2019 | 17 | 0.150 |
Why?
|
| Medical Illustration | 1 | 2019 | 11 | 0.150 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 168 | 0.150 |
Why?
|
| Larynx | 1 | 2019 | 10 | 0.150 |
Why?
|
| Lymph Nodes | 1 | 2019 | 72 | 0.150 |
Why?
|
| Pharynx | 1 | 2019 | 11 | 0.150 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 42 | 0.150 |
Why?
|
| Thyroid Neoplasms | 1 | 2019 | 43 | 0.150 |
Why?
|
| Reference Values | 1 | 2019 | 169 | 0.150 |
Why?
|
| Morphine | 1 | 2019 | 70 | 0.140 |
Why?
|
| Multivariate Analysis | 1 | 2019 | 288 | 0.140 |
Why?
|
| Sweat Gland Neoplasms | 1 | 2018 | 3 | 0.140 |
Why?
|
| Telemedicine | 1 | 2020 | 85 | 0.140 |
Why?
|
| Carcinoma | 1 | 2018 | 68 | 0.140 |
Why?
|
| Sensitivity and Specificity | 2 | 2017 | 445 | 0.130 |
Why?
|
| Invasive Fungal Infections | 1 | 2017 | 5 | 0.130 |
Why?
|
| Mucormycosis | 1 | 2017 | 8 | 0.130 |
Why?
|
| Frozen Sections | 1 | 2017 | 14 | 0.130 |
Why?
|
| Aspergillosis | 1 | 2017 | 13 | 0.130 |
Why?
|
| Analgesics, Opioid | 1 | 2019 | 210 | 0.130 |
Why?
|
| Markov Chains | 1 | 2015 | 30 | 0.120 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2015 | 17 | 0.120 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2015 | 49 | 0.120 |
Why?
|
| Cost-Benefit Analysis | 1 | 2015 | 106 | 0.110 |
Why?
|
| Rhinitis | 1 | 2017 | 136 | 0.110 |
Why?
|
| Neoplasm Metastasis | 1 | 2015 | 102 | 0.110 |
Why?
|
| Sinusitis | 1 | 2017 | 152 | 0.110 |
Why?
|
| Radiotherapy Dosage | 1 | 2014 | 92 | 0.100 |
Why?
|
| Neoplasm Proteins | 1 | 2014 | 52 | 0.100 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 338 | 0.100 |
Why?
|
| Diagnosis, Differential | 2 | 2011 | 314 | 0.100 |
Why?
|
| Drainage | 2 | 2010 | 36 | 0.100 |
Why?
|
| Cricoid Cartilage | 1 | 2012 | 1 | 0.100 |
Why?
|
| Forearm | 1 | 2012 | 18 | 0.090 |
Why?
|
| Mouth Floor | 1 | 2011 | 1 | 0.090 |
Why?
|
| Tongue Diseases | 1 | 2011 | 1 | 0.090 |
Why?
|
| Trachea | 1 | 2012 | 38 | 0.090 |
Why?
|
| Organ Transplantation | 1 | 2012 | 32 | 0.090 |
Why?
|
| Laryngoscopy | 1 | 2011 | 18 | 0.090 |
Why?
|
| Patient Admission | 1 | 2011 | 18 | 0.090 |
Why?
|
| Skin Neoplasms | 1 | 2012 | 66 | 0.090 |
Why?
|
| Otoscopy | 1 | 2010 | 1 | 0.080 |
Why?
|
| Remission, Spontaneous | 1 | 2010 | 8 | 0.080 |
Why?
|
| Hearing Tests | 1 | 2010 | 10 | 0.080 |
Why?
|
| Intubation, Intratracheal | 1 | 2011 | 82 | 0.080 |
Why?
|
| Mediastinal Diseases | 1 | 2010 | 4 | 0.080 |
Why?
|
| Algorithms | 1 | 2011 | 305 | 0.080 |
Why?
|
| Intensive Care Units | 1 | 2011 | 234 | 0.080 |
Why?
|
| Hematoma | 1 | 2010 | 18 | 0.080 |
Why?
|
| Recurrence | 1 | 2010 | 268 | 0.070 |
Why?
|
| Emergency Service, Hospital | 1 | 2011 | 255 | 0.070 |
Why?
|
| Pandemics | 2 | 2020 | 207 | 0.070 |
Why?
|
| Hypertension | 1 | 2010 | 169 | 0.070 |
Why?
|
| Lasers | 1 | 2007 | 14 | 0.070 |
Why?
|
| Embryo, Mammalian | 1 | 2007 | 23 | 0.070 |
Why?
|
| Scattering, Radiation | 1 | 2007 | 32 | 0.070 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2007 | 62 | 0.070 |
Why?
|
| Fetus | 1 | 2007 | 33 | 0.070 |
Why?
|
| Rabbits | 1 | 2007 | 165 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2022 | 578 | 0.050 |
Why?
|
| Printing, Three-Dimensional | 1 | 2023 | 6 | 0.050 |
Why?
|
| Immobilization | 1 | 2023 | 11 | 0.050 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2023 | 47 | 0.050 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2022 | 31 | 0.050 |
Why?
|
| Biology | 1 | 2022 | 7 | 0.050 |
Why?
|
| Apoptosis | 1 | 2022 | 194 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2021 | 226 | 0.040 |
Why?
|
| Animals | 1 | 2007 | 3271 | 0.040 |
Why?
|
| Disease Transmission, Infectious | 1 | 2020 | 19 | 0.040 |
Why?
|
| Nasal Cavity | 1 | 2020 | 31 | 0.040 |
Why?
|
| Emergencies | 1 | 2020 | 28 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2021 | 269 | 0.040 |
Why?
|
| Genomics | 1 | 2020 | 51 | 0.040 |
Why?
|
| Tertiary Care Centers | 1 | 2020 | 66 | 0.040 |
Why?
|
| Mass Screening | 1 | 2020 | 162 | 0.040 |
Why?
|
| Sex Factors | 1 | 2019 | 399 | 0.030 |
Why?
|
| Chicago | 1 | 2020 | 847 | 0.030 |
Why?
|
| Mucor | 1 | 2017 | 5 | 0.030 |
Why?
|
| Aspergillus | 1 | 2017 | 7 | 0.030 |
Why?
|
| Nasal Surgical Procedures | 1 | 2017 | 10 | 0.030 |
Why?
|
| Immunocompromised Host | 1 | 2017 | 42 | 0.030 |
Why?
|
| Nose | 1 | 2017 | 32 | 0.030 |
Why?
|
| Acute Disease | 1 | 2017 | 163 | 0.030 |
Why?
|
| Endoscopy | 1 | 2017 | 167 | 0.030 |
Why?
|
| Decision Making | 1 | 2017 | 179 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2015 | 126 | 0.030 |
Why?
|
| Registries | 1 | 2015 | 174 | 0.030 |
Why?
|